Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:

- Intel (INTC) shares hit their highest level ever after the chipmaker delivered a sales forecast that shattered Wall Street expectations. Revenue will be $13.8 billion to $14.8 billion in the June quarter, the company said Thursday in a statement. Analysts estimated $13 billion on average, according to data compiled by Bloomberg. Intel’s stock soared as much as 28% to $85.22 after trading got underway Friday in New York. It had gained 81% this year heading into the report.

- Charter Communications (CHTR) shares plummeted as much as 20% on Friday, their biggest intraday drop on record, after the cable company reported first-quarter results that featured weaker-than-expected earnings. Analysts also highlighted broadband losses as a disappointment, especially relative to strong results from Comcast.

- Eli Lilly (LLY)’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up with rival Novo Nordisk A/S. Foundayo generated 3,707 prescriptions in its second week, according to IQVIA data cited by RBC Capital Markets analyst Trung Huynh. For comparison, an oral version of Novo’s Wegovy drew 18,410 prescriptions in its second week of launch. Lilly shares fell in New York, while Novo rose in Denmark.

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - Intel (INTC) shares hit their highest level ever after the chipmaker delivered a sales forecast that shattered Wall Street expectations. Revenue will be $13.8 billion to $14.8 billion in the June quarter, the company said Thursday in a statement. Analysts estimated $13 billion on average, according to data compiled by Bloomberg. Intel&rsquo;s stock soared as much as 28% to $85.22 after trading got underway Friday in New York. It had gained 81% this year heading into the report. - Charter Communications (CHTR) shares plummeted as much as 20% on Friday, their biggest intraday drop on record, after the cable company reported first-quarter results that featured weaker-than-expected earnings. Analysts also highlighted broadband losses as a disappointment, especially relative to strong results from Comcast. - Eli Lilly (LLY)&rsquo;s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up with rival Novo Nordisk A/S. Foundayo generated 3,707 prescriptions in its second week, according to IQVIA data cited by RBC Capital Markets analyst Trung Huynh. For comparison, an oral version of Novo&rsquo;s Wegovy drew 18,410 prescriptions in its second week of launch. Lilly shares fell in New York, while Novo rose in Denmark.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. 

Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for five-minute conversations on today's biggest winners and losers in the stock market.&nbsp;
Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Intel Shares Eclipse Dot-Com Peak, Charter Craters, Eli Lilly Slips

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/6df71a50-58b3-4668-92f5-b4360115f0a1/transcript